A causal role for remnant cholesterol in TG-rich lipoproteins such as VLDL has previously been suggested by meta-analysis and large-scale Mendelian randomization studies (4, 5) . Similarly, mass spectrometry-based proteomics in the Bruneck study ranked 3 VLDL-associated apolipoproteins-apolipoprotein C3, apolipoprotein C2, and apolipoprotein Eas first to third with regard to CVD risk prediction (6) .
However, these data must be interpreted in the context of the widespread use of statins for primary prevention in this cohort. Emerging studies suggest that cause for MI is shifting from plaque ruptures to plaque erosions, possibly due to the widespread use of LDL-C lowering therapies (7, 8) . With low LDL-C levels, the relative contribution of TG-rich lipoproteins to CVD risk may increase.
The China Kadoorie Biobank study (3) reported that he has no relationships relevant to the contents of this paper to disclose. features. The Chinese Kadoorie Biobank study (3) suggests that the TG rather than the cholesterol content of HDL is a determinant of atherogenicity.
Finally, circulating glycoprotein N-acetylglucosamine residues-a glycan biomarker linked to inflammation and aging-showed one of the strongest associations across all 3 main vascular endpoints (MI, IS, and ICH).
More studies are required to scrutinize these associations and to further explore cause and effect.
We are entering a new era of lipid management (12, (14) (15) (16) . With a growing armamentarium of lipidlowering therapies, patients can be more readily treated to achieve the recommended LDL-C target levels. Besides LDL-C, the therapeutic focus may broaden to tackle the residual CVD risk and include VLDL and TGs (3-6,23), as well as fatty acid composition (9, 24) and other apolipoproteins, that is, lipoprotein (a) (10) (11) (12) . It is time to advance NMR spectroscopy and mass spectrometry technologies for lipoprotein and apolipoprotein profiling to meet the high throughput, low cost, and standardization required for potential clinical use (25, 26) . The application of multiomics technologies may pave the way toward redefining CVD risk (27).
